A visionary entrepreneur, Arie is the co-founder and Executive Chairman of Allogene Therapeutics, a biotechnology company with a mission to catalyze the next revolution in cancer treatment through the development of allogeneic chimeric antigen receptor T-cell (CAR T) therapy directed at blood cancers and solid tumors. He is also the founding Chairman of Kronos Bio, a biopharmaceutical company dedicated to the discovery and development of novel cancer therapeutics targeting dysregulated transcription. Arie previously founded Kite Pharma, a biopharmaceutical company engaged in the development of innovative cancer immunotherapies where he served as Chairman, President, and Chief Executive Officer until the acquisition of Kite by Gilead Sciences in October 2017. Arie has had a distinguished tenure in the life sciences, having been closely involved with the founding and advancement of several successful biopharmaceutical companies including Cougar Biotechnology and Agensys. Abiraterone, developed by Cougar, is a mainstay of therapy for patients with metastatic prostate cancer. He currently serves as Chairman of Two River Group and UroGen Pharma, Kronos Bio, and Bellco Capital, and as co-Chairman of Breakthrough Properties LLC. He serves as director of IconOVir Bio, Inc. and is also co-Founder and Senior Managing Director of Vida Ventures, a life science venture group with offices in Boston and Los Angeles.
Arie is a Research Professor, holds the Roy and Carol Doumani Chair in Urologic Oncology, and is Founder and Director of the UCLA Institute of Urologic Oncology at the David Geffen School of Medicine at UCLA.
Prior to joining UCLA, Arie was at the National Cancer Institute/NIH as a research fellow in surgical oncology and immunotherapy under Dr. Steven A. Rosenberg. He completed his M.D. at the Hebrew University Hadassah Medical School in Jerusalem, his post-graduate studies in Immunology at the Weizmann Institute of Science, and his residency in Urologic Surgery at Harvard Medical School. He has authored several books in oncology and more than 500 scientific and medical papers related to urological cancers, immunotherapy, gene therapy, and cancer vaccines. He is certified by the American Board of Urology and is a Fellow of the American Association of Genitourinary Surgeons.
Register for Updates
Two River 689 Fifth Avenue, 12th Floor New York, New York 10022 212.871.7900
The technical storage or access is strictly necessary for the legitimate purpose of enabling the use of a specific service explicitly requested by the subscriber or user, or for the sole purpose of carrying out the transmission of a communication over an electronic communications network.
The technical storage or access is necessary for the legitimate purpose of storing preferences that are not requested by the subscriber or user.
The technical storage or access that is used exclusively for statistical purposes.The technical storage or access that is used exclusively for anonymous statistical purposes. Without a subpoena, voluntary compliance on the part of your Internet Service Provider, or additional records from a third party, information stored or retrieved for this purpose alone cannot usually be used to identify you.
The technical storage or access is required to create user profiles to send advertising, or to track the user on a website or across several websites for similar marketing purposes.